-+ 0.00%
-+ 0.00%
-+ 0.00%

Ionis says diranersen slows clinical decline in early Alzheimer’s at two years

PUBT·11/17/2026 21:45:37
Listen to the news
Ionis says diranersen slows clinical decline in early Alzheimer’s at two years
  • Ionis Pharmaceuticals reported increasing clinical benefit from investigational diranersen in early Alzheimer's disease over two years in the Phase 2 CELIA trial.
  • Partner Biogen presented the results at the 2026 Clinical Trials on Alzheimer's Disease conference.
  • Treatment slowed cognitive and functional decline, with the 60 mg twice-yearly regimen showing the largest effects at two years.
  • The two-year analysis compared continued treatment with participants initially assigned placebo who received little or no diranersen during the open-label extension.
  • Diranersen was generally well tolerated through two years, with no new safety signals observed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261117852253) on November 17, 2026, and is solely responsible for the information contained therein.